Michel P. Ducreux

Michel P. Ducreux's AcademicInfluence.com Rankings

Michel P. Ducreux

Medical

#1753

World Rank

#2126

Historical Rank

Gastroenterology

#28

World Rank

#30

Historical Rank

Oncology

#90

World Rank

#94

Historical Rank

medical Degrees

Michel P. Ducreux

Philosophy

#5287

World Rank

#8047

Historical Rank

Logic

#2591

World Rank

#3603

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Michel P. Ducreux's Degrees

Doctorate Medicine Université Paris Cité
PhD Oncology Université Paris Cité

Why Is Michel P. Ducreux Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michel P. Ducreux's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. (2011) (4954)
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (3188)
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (2654)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) (2450)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (2006) (2217)
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. (2006) (1625)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (2008) (1528)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. (2005) (947)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (947)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. (2001) (939)
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010) (912)
Immunogenic death of colon cancer cells treated with oxaliplatin (2010) (877)
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. (2000) (771)
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (2009) (687)
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of (2000) (539)
Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? (2009) (525)
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin (1999) (462)
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy (2001) (435)
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. (2000) (396)
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. (1998) (379)
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma (1999) (348)
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. (2002) (345)
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. (2014) (337)
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. (2005) (334)
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 (2015) (333)
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. (2006) (333)
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. (2002) (308)
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. (1998) (297)
Are G3 ENETS neuroendocrine neoplasms heterogeneous? (2013) (286)
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. (2012) (284)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017) (277)
Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect (2005) (263)
ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer (2005) (251)
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. (2003) (243)
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors (2002) (241)
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. (2021) (228)
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. (2005) (221)
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. (2003) (219)
Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis (2011) (218)
Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy? (2013) (212)
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. (2011) (207)
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. (1998) (201)
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. (2007) (200)
Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. (2002) (194)
A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs (2015) (190)
Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. (1998) (186)
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) (2007) (182)
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. (1996) (181)
Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure (2007) (181)
Peritoneal carcinomatosis of colorectal origin. (2006) (173)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). (2021) (172)
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. (2014) (172)
Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease (2004) (172)
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. (2004) (171)
Transcatheter chemoembolization of progressive carcinoid liver metastasis. (1993) (170)
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). (2009) (168)
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. (1998) (162)
MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. (2003) (161)
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) (2019) (160)
Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. (2012) (158)
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer (2015) (155)
Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases (1998) (154)
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. (2010) (153)
Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer (2011) (151)
Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis (2008) (149)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. (2019) (148)
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. (2011) (145)
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). (2005) (144)
Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. (2014) (143)
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. (1995) (134)
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. (2012) (133)
Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. (2006) (133)
Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. (2004) (130)
Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. (1998) (129)
Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin (2007) (126)
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. (2005) (126)
Current standards and new innovative approaches for treatment of pancreatic cancer. (2016) (124)
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. (2002) (124)
Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. (2013) (123)
An update on treatment options for pancreatic adenocarcinoma (2019) (122)
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. (2011) (121)
Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases (2010) (121)
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. (2002) (118)
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. (2009) (117)
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. (1999) (116)
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. (1994) (115)
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. (2009) (112)
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. (2014) (112)
Liver abscess formation after local treatment of liver tumors (1996) (111)
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. (2010) (107)
CPT-11 (irinotecan) in the treatment of colorectal cancer. (1995) (104)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. (2017) (103)
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. (1999) (103)
Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy (2004) (100)
Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. (2015) (100)
Human Pharmacokinetic Study of Heated Intraperitoneal Oxaliplatin in Increasingly Hypotonic Solutions after Complete Resection of Peritoneal Carcinomatosis (2002) (100)
Cetuximab plus Gemcitabine-Oxaliplatin (GEMOX) in Patients with Refractory Advanced Intrahepatic Cholangiocarcinomas (2007) (99)
Self-expanding metallic stents as palliative treatment of malignant gastroduodenal stenosis. (1997) (98)
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. (2012) (96)
GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. (2015) (96)
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. (2002) (95)
Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. (2011) (94)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. (2004) (93)
High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. (2001) (92)
Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents. (2005) (92)
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. (2004) (91)
Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma (2005) (90)
Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. (2013) (90)
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial (2003) (89)
mTOR as a therapeutic target in patients with gastric cancer (2012) (87)
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. (2016) (87)
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer (2013) (87)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. (2014) (85)
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. (2018) (83)
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. (2021) (83)
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial (2007) (82)
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. (2014) (81)
Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. (1996) (80)
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. (2016) (80)
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. (2002) (79)
A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial (2013) (78)
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model (2004) (76)
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. (1994) (76)
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. (2019) (76)
Systemic treatment of pancreatic cancer revisited. (2019) (75)
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (2003) (75)
Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France (2008) (72)
[Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. (2008) (72)
Molecular targeted therapy of BRAF-mutant colorectal cancer (2019) (72)
Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence: A Comparative Study Between Hepatic Arterial Infusion of Oxaliplatin and Modern Systemic Chemotherapy (2013) (71)
Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. (2015) (71)
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. (2002) (71)
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC (2013) (71)
Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas (2018) (71)
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. (1993) (71)
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. (2005) (69)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. (2014) (69)
Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394). (2018) (68)
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. (2000) (67)
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. (2016) (67)
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2018) (66)
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. (2012) (66)
The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. (2008) (65)
Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. (2009) (65)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. (2006) (64)
Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring (2007) (64)
GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III. (2004) (64)
Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. (2010) (63)
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. (2008) (63)
Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. (1997) (62)
Gender Medicine and Oncology: Report and consensus of an ESMO Workshop. (2019) (61)
Pancreatic cancer treatment and research: an international expert panel discussion. (2011) (61)
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas (2007) (59)
Benefits of contrast-enhanced sonography for the detection of liver lesions: comparison with histologic findings. (2008) (59)
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. (2006) (59)
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). (2014) (58)
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. (2015) (56)
A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases (2014) (54)
Leukocytosis and neutrophilia predicts outcome in anal cancer. (2017) (54)
Artificially induced pneumothorax for percutaneous transthoracic radiofrequency ablation of tumors in the hepatic dome: initial experience. (2005) (54)
Improving outcomes in colorectal cancer: where do we go from here? (2013) (53)
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) (2016) (53)
Imaging of neuroendocrine tumors of the pancreas. (2016) (52)
Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. (2004) (52)
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. (1999) (52)
Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). (2017) (52)
Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. (1994) (52)
Preoperative chemotherapy of locally advanced gastric cancer. (1994) (51)
5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. (1997) (51)
Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. (1995) (50)
Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. (1991) (50)
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. (2018) (48)
Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases (2010) (48)
Oxaliplatin in colorectal cancer: an overview. (2000) (48)
Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (2007) (47)
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. (2012) (47)
Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer (2013) (46)
Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. (2008) (45)
Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2019) (45)
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. (2005) (45)
Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. (2019) (44)
IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (2018) (44)
3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. (2017) (44)
Intra-Arterial Hepatic Chemotherapy: A Comparison of Percutaneous Versus Surgical Implantation of Port-Catheters (2011) (42)
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. (2011) (42)
Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (41)
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. (2006) (41)
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. (2000) (41)
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. (2019) (41)
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. (2001) (41)
Thyroid metastases from colorectal cancer: the Institut Gustave Roussy experience. (2006) (41)
Treatment of advanced pancreatic cancer. (2007) (41)
The role of image-guided therapy in the management of colorectal cancer metastatic disease. (2017) (40)
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (40)
Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study (2011) (38)
Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients (2013) (38)
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. (2017) (38)
Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin (2004) (38)
Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. (2016) (38)
Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. (2004) (37)
Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. (1995) (37)
Esophageal prothesis for neoplastic stenosis. A prognostic study of 77 cases (1986) (37)
Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. (2010) (36)
Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft. (2007) (36)
Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation (2017) (36)
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. (2017) (35)
Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect? (2011) (34)
14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) (2009) (34)
Ex Vivo Sentinel Lymph Node Study For Rectal Adenocarcinoma: Preliminary Study (2005) (34)
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG (2017) (34)
Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial (2007) (34)
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. (2018) (33)
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. (1997) (33)
Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. (1999) (33)
Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome (2011) (33)
Joint model for left‐censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial (2016) (33)
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. (2015) (33)
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (2018) (32)
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer (2009) (32)
Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results (2007) (31)
Predisposing Factors of Liver Necrosis after Transcatheter Arterial Chemoembolization in Liver Metastases from Neuroendocrine Tumor (2015) (31)
Immune scores in colorectal cancer: Where are we? (2020) (31)
Biliary tract neoplasms: update 2003 (2004) (30)
Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. (1997) (30)
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy (2017) (29)
Peritoneal carcinomatosis of colorectal origin Long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery (2006) (28)
Serum Gamma-Glutamyl-Transferase Independently Predicts Outcome After Transarterial Chemoembolization of Hepatocellular Carcinoma: External Validation (2012) (27)
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. (2003) (27)
Usefulness of Guiding Needles for Radiofrequency Ablative Treatment of Liver Tumors (2006) (27)
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. (2018) (26)
A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 ) (2009) (25)
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. (2003) (25)
Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). (2016) (25)
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study (2019) (25)
A Phase II Study of Irinotecan with 5-Fluorouracil and Leucovorin in Patients with Pretreated Gastroenteropancreatic Well-Differentiated Endocrine Carcinomas (2006) (25)
A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. (1997) (25)
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. (1991) (24)
Gender medicine and oncology: report and consensus of an ESMO workshop. (2019) (24)
Management of colorectal peritoneal metastases: Expert opinion. (2019) (24)
Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer (2006) (24)
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. (2007) (23)
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground? (2017) (23)
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer (2009) (23)
Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. (2004) (23)
Central retroperitoneal recurrences from colorectal cancer: are lymph node and locoregional recurrences the same disease? (2012) (23)
Adjuvant chemotherapy in locally advanced bladder cancer (2015) (23)
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). (2020) (23)
Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. (2017) (22)
Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial (2018) (22)
Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art. (2015) (22)
LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) (2015) (22)
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6 (2011) (22)
[Peritoneal carcinosis treated by complete excision and immediate postoperative intra-peritoneal chemotherapy. Phase II study in 54 patients]. (1997) (22)
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. (2016) (22)
Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications (2016) (21)
Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers. (2013) (21)
The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study (2009) (20)
MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach (2018) (20)
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. (2019) (20)
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. (2013) (20)
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. (2000) (20)
High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases? (2008) (20)
[Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. (1999) (20)
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. (2017) (20)
[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin]. (1992) (20)
Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results (2008) (20)
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. (2014) (20)
Oxaliplatin for the treatment of advanced colorectal cancer: future directions. (1998) (20)
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. (1997) (19)
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies (2014) (19)
Imagine a world without cancer (2014) (19)
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO). (2012) (19)
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. (2000) (19)
Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study. (2010) (18)
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE) (2017) (18)
Impact of COVID-19 on healthcare organisation and cancer outcomes (2021) (18)
Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study (2019) (18)
Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients' data from four randomized trials. (2012) (18)
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. (2017) (18)
O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma (2021) (17)
Efficacy of chemoembolization for hepatocellular carcinomas: Experience from the gustave roussy institute and the bicetre hospital (1993) (17)
[Treatment of peritoneal carcinomatosis using complete excision and intraperitoneal chemohyperthermia. A phase I-II study defining the best technical procedures]. (1999) (17)
Disseminated and circulating tumor cells in gastrointestinal oncology. (2012) (17)
Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. (2006) (17)
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients (2001) (16)
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis (2011) (16)
Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect? (2018) (16)
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228) (2017) (16)
Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors (2009) (16)
Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool. (2015) (15)
Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). (2012) (15)
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. (2016) (15)
RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. (2018) (15)
Treatment sequence of synchronously (liver) metastasized colon cancer. (2016) (15)
Intervention in gastro-enteropancreatic neuroendocrine tumours. (2012) (15)
Pancreatic cancer: From pathogenesis to cure (2007) (15)
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study. (2005) (15)
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer (2008) (14)
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973) (2018) (14)
Value of cardiophrenic angle lymph node for the diagnosis of colorectal peritoneal carcinomatosis. (2013) (14)
Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg (1998) (14)
Immunotherapy in Advanced Biliary Tract Cancers (2021) (14)
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). (2021) (14)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2022) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Circumferential pharyngolaryngectomy with total esophagectomy for locally advanced carcinomas (1998) (13)
Liver, lung and peritoneal metastases in colorectal cancers: is the patient still curable? What should the radiologist know. (2014) (13)
Systemic chemotherapy of advanced digestive neuroendocrine tumours. (1999) (13)
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. (2018) (13)
Cetuximab Therapy in Colorectal Cancer Mutation Status Is Predictive of Response to KRAS Updated (2006) (13)
Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab. (2011) (13)
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). (2006) (13)
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer (2021) (13)
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival (2011) (12)
Simultaneous decompression colonoscopy and radiologic G-tube insertion in a patient with megacolon because of chronic colonic pseudo-obstruction. (2005) (12)
Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP) (2008) (12)
Splenic infarction and bevacizumab. (2006) (12)
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. (2020) (12)
[Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis]. (1999) (12)
Calcemic response to magnesium or 1-alpha-hydroxycholecalciferol treatment in intestinal hypomagnesemia. (1991) (12)
Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment. (2007) (12)
[Effect of alcohol and cirrhosis on the presence of Helicobacter pylori in the gastric mucosa]. (1990) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. (2020) (11)
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. (2020) (11)
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT) (2017) (11)
[Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system]. (2000) (11)
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy (2019) (11)
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. (1998) (10)
Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: preliminary safety results. (2008) (10)
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). (2017) (10)
[Treatment strategy of neuroendocrine tumors]. (2002) (10)
Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study (2016) (10)
Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC) (1999) (10)
3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results (2007) (10)
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) (2021) (10)
Antitumoral effect of celecoxib in hepatocellular carcinoma. (2005) (10)
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial (2016) (10)
An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. (2004) (9)
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers. (2021) (9)
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. (2014) (9)
Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. (2013) (9)
Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting (2007) (9)
Abdominoperineal resection combined with pre- and postoperative radiation therapy in the treatment of low-lying rectal carcinoma. (1997) (9)
Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis (2005) (9)
612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH. (2014) (9)
No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer (2019) (9)
546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT. (2014) (9)
Surgical treatment of severe late radiation injury to the bowel: a retrospective analysis of 83 cases. (2002) (9)
Pelvectomie totale et cancer du rectum. À propos de 20 observations (1999) (8)
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. (2021) (8)
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. (2020) (8)
Adjuvant treatment of pancreatic cancer. (2019) (8)
Gastric linitis adenocarcinoma and carcinomatous meningitis: an infrequent but aggressive association--report of four cases. (2001) (8)
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology (2018) (8)
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. (2000) (8)
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. (2012) (8)
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR) (2020) (8)
Results of lymphadenectomy for obvious lateroaortic lymph node metastases from colorectal primaries. (2001) (8)
CHIMIOTHERAPIE INTRA-ARTERIELLE HEPATIQUE. EXPERIENCE DE 200 CAS (1994) (8)
Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study). (2012) (8)
Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). (2012) (7)
The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. (2007) (7)
Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience (2021) (7)
IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703. (2015) (7)
More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer (2018) (7)
[5-fluorouracil: metabolism and current indications in digestive cancer treatment]. (2002) (7)
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin. (1989) (7)
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. (2016) (7)
Future directions in drug development in pancreatic cancer. (2021) (7)
Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. (2017) (7)
Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor (2016) (7)
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study. (2004) (6)
[Therapeutic strategies using VEGF inhibitors in colorectal cancer]. (2005) (6)
Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Peritoneal Carcinomatosis of Digestive and Peritoneal Origin: Rationale (2006) (6)
Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. (2016) (6)
A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients (pts). (2010) (6)
Cetuximab plus gemcitabine/oxaliplatin (GEMOX) for patients with unresectable/recurrent intrahepatic cholangiocarcinoma refractory to GEMOX. (2006) (6)
[Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. (2008) (6)
6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study) (2009) (6)
Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors. (2013) (6)
A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer (2008) (6)
[Complications and tolerance of heated intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis: results of a phase I-II study of peritoneal carcinomatosis from different sources]. (2000) (6)
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers (2021) (6)
Cancer of the rectum (2001) (6)
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer (2022) (6)
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. (2002) (6)
554 Demonstrated efficiency of 5fluorouracil (5FU) continuous infusion (CI) and cisplatin (P) in patients with advanced biliary tract carcinoma (1995) (6)
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? (2017) (6)
548PIMPACT OF BASELINE COVARIATES AND PRIOR THERAPY ON THE EFFICACY OF SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT. (2014) (6)
[Control of perfusion by angioscintigraphy during hepatic intra-arterial chemotherapy]. (1989) (6)
[Gastroduodenal complications of hepatic intra-arterial chemotherapy of hepatic metastases of colorectal origin]. (1989) (5)
Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study. (2019) (5)
Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study. (2017) (5)
[What are the real indications for hepatectomies in metastases of colorectal origin?]. (1998) (5)
1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC (2020) (5)
[Radiotherapy of malignant tumors of the liver]. (1995) (5)
Review of the current status of KRAS mutation testing in France in 2011: The Flash-KRAS study. (2012) (5)
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors (2017) (5)
Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC). (2012) (5)
[Treatment of malignant gastric or duodenal stenoses by the insertion of metallic prostheses under fluoroscopic control]. (1998) (5)
Body-mass index, cancer, and implications for screening. (2015) (5)
6094 POSTER Impact of Early Tumour Shrinkage on Long-term Outcome in Metastatic Colorectal Cancer (mCRC) Treated With 5FU+lrinotecan+Leucovorin (FOLFIRI) or Capecitabine+lrinotecan XELIRI Plus Bevacizumab (2011) (5)
Methylprednisolone‐induced immune thrombocytopenia (2020) (5)
[Colorectal cancer: prognostic molecular markers]. (2004) (5)
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC) (2021) (5)
Prevalence of hepatitis C virus RNA in suspected drug induced liver diseases. (1993) (5)
[Standards, options and recommendations for the management of patients with primary adenocarcinoma of the rectum. National Federation of Centers for the Fight against Cancer]. (1999) (5)
Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study. (2018) (5)
[Septicemias after endoscopic retrograde cholangiopancreatography. Risk factors and antibiotic prophylaxis]. (1993) (5)
Intra-arterial hepatic chemotherapy with oxaliplatin combined to intravenous treatment with 5FU + folinic acid in hepatic metastases of colorectal cancer (2001) (4)
Safety of bevacizumab in cancer patients with inflammatory bowel disease. (2019) (4)
Are we reproducible in measurement of NET liver metastasis? (2017) (4)
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. (2014) (4)
Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. (2021) (4)
6113 POSTER Efficacy and Safety at 12 Months of 1st Line Bevacizumab (Bv) Plus Chemotherapy (CT) in Elderly Patients (Pt) With Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice – the CONCERT French Observational Cohort Study (2011) (4)
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer (1998) (4)
Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC). (2004) (4)
Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification for the early evaluation of hepato cellular carcinoma treated by bevacizumab in phase II (2008) (4)
Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150. (2018) (4)
The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management (2012) (4)
Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (2016) (4)
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. (2013) (4)
patients with advanced pancreatic carcinoma (2014) (4)
[Nilutamide-induced acute hepatitis]. (1991) (4)
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC). (2020) (4)
Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors (2021) (4)
XELOX regimen in elderly patients with metastatic colorectal cancer (MCRC), a FNCLCC French Collaborative Group GERICO 02 phase II study (2007) (4)
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]. (2004) (4)
Neuroendocrine tumors and CUP (2012) (4)
IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (2018) (4)
[Resectional treatment of peritoneal carcinomatosis followed by intraperitoneal chemotherapy, practical aspects]. (2003) (4)
Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228). (2014) (4)
P1-123: Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients. (2007) (4)
[Total pelvic exenteration and rectal cancer. Apropos of 20 cases]. (1999) (4)
[Metastatic colorectal cancer: To stop or not to stop?] (2018) (4)
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. (2008) (3)
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. (2021) (3)
Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130]. (2018) (3)
Radiotherapy for localized rectal cancer. (2007) (3)
Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. (2019) (3)
Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study. (2017) (3)
PD-0002KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB + FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS (2014) (3)
Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. (2016) (3)
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. (2017) (3)
[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis]. (1995) (3)
Neoadjuvant chemotherapy (NCT) in locally advanced gastric carcinoma (LAGC) (1993) (3)
Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC (2021) (3)
[Value of endorectal ultrasonography in the treatment of rectal tumors]. (1996) (3)
[Treatment of metastatic malignant insulinomas. 2 cases]. (1995) (3)
[Fenofibrate-induced acute hepatitis with pseudo-cholangitis]. (1992) (3)
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study. (2018) (3)
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion? (2017) (3)
The role of irinotecan in the treatment of colorectal cancer metastases: surgeons and oncologists in partnership (2004) (3)
Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes? (2016) (3)
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. (2006) (3)
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. (2021) (3)
[Adjuvant treatment of colorectal cancers]. (1994) (3)
Protective effect of an enteral formula containing TGF-β2 in the prevention of chemotherapy-induced diarrhoea: A pilot study (2009) (3)
Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer (2007) (3)
Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study (2011) (3)
[Primary ano-rectal melanoma. Report of 9 cases]. (1996) (3)
Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. (2021) (3)
Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. (2021) (2)
[The new chemotherapy of colorectal cancers]. (2002) (2)
[Positron emission tomography in digestive tract cancer]. (2002) (2)
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? (2016) (2)
CA 19-9 and Pancreatic Carcinoma, a Revival? (2007) (2)
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study (2022) (2)
More patients needed in stage II colon cancer trials. (2000) (2)
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid]. (1983) (2)
Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC) (2004) (2)
A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. (2016) (2)
O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial (2021) (2)
Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003–03 trial) (2005) (2)
Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC) (2021) (2)
Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study. (2018) (2)
Emerging drugs in pancreatic cancer (2004) (2)
Vision loss after chemotherapy: an irinotecan-induced retinopathy. (2019) (2)
[Major hepatectomy after intra-arterial chemotherapy for initially unresectable liver tumors. Frequency, technical problems, results and indications]. (1996) (2)
[Hepatic metastases of colorectal cancers: intra-arterial chemotherapy. Value and indications]. (1996) (2)
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]. (1999) (2)
PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC). (2018) (2)
Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors (2020) (2)
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion? (2013) (2)
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease (2022) (2)
Phase I/II study of CPT-11 in combination with LV2FU5 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5FU failure (1997) (2)
Phase I study of first line radiochemotherapy (RCT) with oxaliplatin (Ox), fluorouracil (FU) and folinic acid (FA) in inoperable locally advanced (LA) or metastatic (m) esophageal cancer (EC). (2004) (2)
[Prevention and treatment of chemotherapy-induced digestive toxicities]. (2001) (2)
A Phase II Trial of Bevacizumab Combined with Chemotherapy in Patients with Metastatic Well-Differentiated Duodeno-Pancreatic Endocrine Tumors (Better Study) (2012) (2)
Patients with initially irresectable colorectal liver metastases: Is there a possibility of cure by an oncosurgical approach? (2008) (2)
Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial (2019) (2)
EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING (2007) (2)
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial (2022) (2)
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49 (2022) (2)
Surrogate endpoints in neoadjuvant rectal cancer trials: Statistical evaluation using data from the FFCD 9203 trial (2008) (2)
[Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]. (2001) (2)
LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach (2015) (2)
International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer. (2012) (2)
French guidelines for digestive cancers. (2006) (2)
93 TiPPatient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma (2017) (2)
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study (2019) (2)
Treatment algorithm for hepatocellular carcinoma (2010) (2)
1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC) (2022) (2)
[Expert agreement on the minimal descriptive surgical report for peritoneal cancer]. (2007) (2)
O-0007 Exploratory Serum Biomarker Analyses from BO21129, a Phase II Study of Erlotinib in Second-Line Pancreatic Cancer: Potential Role of Amphiregulin? (2012) (2)
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC (2020) (2)
Selecting the right chemotherapy in first line advanced squamous cell carcinoma of the anus. (2021) (2)
70P Genomic landscape and efficacy of precision medicine in biliary tract cancers (2020) (2)
Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. (2016) (2)
[Radiation-induced stricture of the papilla and the common bile duct: successful treatment with balloon dilation]. (2001) (2)
Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260). (2017) (2)
Immunotherapy and Hepatocellular Cancer: Where Are We Now? (2022) (2)
Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancer. (2022) (2)
[Irinotecan in combination for colon cancer]. (1998) (2)
[Non-invasive imaging tools in colorectal cancer]. (2010) (1)
613TiPA PROSPECTIVE, OBSERVATIONAL TRIAL TO FURTHER ASSESS SAFETY AND EFFICACY OF REGORAFENIB IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN ROUTINE CLINICAL PRACTICE (CORRELATE). (2014) (1)
932P IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor) (2021) (1)
Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005 (2006) (1)
Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures. (2018) (1)
Biliary cancers, chemotherapy, and cetuximab. (2010) (1)
Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE). (2019) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. (2021) (1)
REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. (2016) (1)
Antibodies to hepatitis C virus in patients with positive HBsAg (1990) (1)
Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review. (2014) (1)
Oncology and public health (2012) (1)
1077TiPIMMUNOMODULATORY MAINTENANCE THERAPY WITH TLR-9 AGONIST MGN1703 IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA-THE RANDOMIZED PHASE 3 IMPALA STUDY. (2014) (1)
[Efficacy of chemotherapy and combined chemo-radiotherapy in gastric adenocarcinoma]. (1989) (1)
Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228 (2013) (1)
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica (2018) (1)
[Recent advances in adjuvant chemotherapy in colonic cancers]. (1997) (1)
Cost assessment of first line chemotherapy in metastatic colorectal cancer (2008) (1)
[Importance of a multidisciplinary approach to metastatic cancer of the rectum]. (1998) (1)
Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. (2020) (1)
Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. (2020) (1)
6575 Bevacizumab combined with chemotherapy in the treatment of advanced/metastatic gastro-entero-pancreatic tumours: interim safety results from the phase II BETTER study (2009) (1)
FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? (2022) (1)
Can patients be cured after cytoreductive surgery plus intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis? (2011) (1)
80. EORTC-1409: An EORTC-ESSO prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB) NCT02218801 (2016) (1)
Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial. (2010) (1)
169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC (2020) (1)
888MO Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors (2022) (1)
Value of cardiophrenic angle lymph nodes for the diagnosis of colorectal peritoneal carcinomatosis. (2013) (1)
Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials. (2016) (1)
Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study (2020) (1)
EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM). (2017) (1)
Relationship between high dose irinotecan (260mg/m2) and response rate, without increased toxicities in metastatic colorectal cancer (MCRC) combination with bi-weekly 5FU/FA in a phase II study (2001) (1)
3076 Tumor control of advanced pulmonary carcinoid tumors with somatostatin analogs: Experience at Gustave Roussy (2015) (1)
Imagine a world without cancer (2014) (1)
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial (2019) (1)
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]. (1999) (1)
1402 POSTER DISCUSSION CT Evaluation of the Response of Colorectal Liver Metastasis After Bevacizumab Treatment – a Density Quantitative Analysis Correlated With Patient Outcome (2011) (1)
Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC). (2004) (1)
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study. (2022) (1)
Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study. (2016) (1)
An appraisal of emerging second line therapies for metastatic colorectal cancer (2020) (1)
Phase I and pharmacokinetic study of BBR 2778 (1999) (1)
[Adjuvant therapy of cancer of the rectum]. (1996) (1)
Hepatic Arterial Infusion (HAI) of Oxaliplatin Plus Intravenous (IV) Fluorouracil (FU), Leucovorin (LV) and Cetuximab for First-Line Treatment of Unresectable Colorectal Liver Metastases (CRLM): Final Results of a Multicenter Phase 2 Study (CHOICE) (2012) (1)
[Linitis of the colon with peritoneal carcinosis treated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy]. (2007) (1)
420 Flash RAS study: RAS testing assessment in patients with metastatic colorectal cancer in 2014 (2015) (1)
Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals. (2021) (1)
725 Pulmonary metastases (PM) from colorectal cancer (CRC) treated by surgical resection. Prognostic factor analysis (1995) (1)
Fatigue and health behaviors in cancer survivors: A cross-sectional population based study. (2017) (1)
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]. (2021) (1)
Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577) (2004) (1)
[Docetaxel and gastric cancer]. (2004) (1)
Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study (2015) (1)
Unresected hepatic metastases (HM) from colorectal cancer (CRC). Prospective prognostic factor analysis on 544 cases from fondation Française de cancerologie digestive (FFCD) (1993) (1)
[Iatrogenic ligation of the common bile duct. Diagnostic value of percutaneous insertion of an angioplasty balloon catheter]. (1990) (1)
Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. (2022) (1)
Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin. (2009) (1)
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. (2019) (1)
[Is D-lactate assay useful for the diagnosis of ascitic infection in patients with liver cirrhosis?]. (1993) (1)
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. (1998) (1)
Genome-wide expression profiling and tissue array analysis for prediction of recurrences in stage II-III colorectal cancer (CRC). (2006) (1)
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy (2023) (1)
[Exudative gastropathy associated with cytomegalovirus infection after allogenic bone marrow transplantation]. (1994) (1)
Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial. (2009) (1)
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]. (2006) (1)
Emerging drugs in pancreatic cancer. (2004) (1)
Adjuvant chemotherapy for colon cancer. (2002) (1)
Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study. (2023) (0)
230 Fifteen-month registration of patients with digestive endocrine tumors (DET) in France (FFCD-ANGH-GERCOR study) (2003) (0)
[Locoregional chemotherapy of hepatic metastases of colorectal cancer]. (1987) (0)
A282 EUS GUIDED FIDUCIAL PLACEMENT FOR PANCREATIC TUMORS AND TECHNICAL ISSUES IN ANTICIPATION OF STEREOTACTIC RADIATION THERAPY (2019) (0)
Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228). (2014) (0)
Phase 2 of intra-arterial hepatic (IAH) bevacizumab with systemic chemotherapy (CT) in second line treatment of liver metastases of colorectal cancer (LMCRC) (2016) (0)
Reply to R. Glynne-Jones et al. (2013) (0)
Is intra-arterial hepatic chemotherapy painful? (2019) (0)
[Gastric lymphoma: natural history and classification]. (1996) (0)
[Positron emission tomography and gastrointestinal oncology]. (2003) (0)
9097 POSTER Effect of Somatostatin Analogs in the Control of Tumour Growth in Patients With Metastatic Lung Carcinoid Tumours (2011) (0)
Dosage A djustment a nd P harmacokinetic P rofile o f I rinotecan in C ancer P atients W ith H epatic D ysfunction (2002) (0)
Abstract 2306: The prognostic impact of epithelial mesenchymal transition markers in primary diffuse gastric carcinoma and their relative lymph nodes (2010) (0)
[Management of metastatic neuroendocrine tumors]. (2011) (0)
Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. (2018) (0)
The French experience with infusional 5-FU in gastric and pancreatic cancer. (1996) (0)
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab (2022) (0)
Role of precision medicine for patients with advanced biliary tract cancers. (2020) (0)
Neuropathy and health behaviors in cancer survivors treated with chemotherapy (CT). (2018) (0)
Predictive Value of Circulating Endothelial Cell (CEC) Levels in Metastatic or Locally Advanced Neuroendocrine Digestive Tumor Patients Treated With Chemotherapy and Bevacizumab (2012) (0)
76 INVITED Treatment of non-operable pancreatic cancer. The role of Tarceva (2007) (0)
Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer. (2019) (0)
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. (2023) (0)
Systemic treatment of advanced biliary cancers: present and future (2012) (0)
[Oral treatments for cancer]. (2019) (0)
Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV). (2017) (0)
L'irinotecan en association dans le cancer du côlon (1998) (0)
Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology) (2008) (0)
Chemotherapy for colorectal cancer – Authors' reply (2012) (0)
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma. (2021) (0)
Results from the PROPHYLOCHIP-PRODIGE 15 trial - Authors' reply. (2020) (0)
1047P Long terms efficacy of anti-PD(L)1 in MSI tumours (2020) (0)
Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfynction (1999) (0)
Efficacy and Safety of Bevacizumab Combined with Chemotherapy in Daily Practice in 765 French Patients with MCRC: The Concert Cohort at a Maximum of 24 Months Follow-Up (2012) (0)
Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial (2010) (0)
705PPREMATURE MORTALITY IN PANCREATIC CANCER: ANALYSIS OF LOST LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN EUROPE. (2014) (0)
Liver Metastases of Other Indications (2015) (0)
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]. (2008) (0)
Tumor marker kinetics: Better than imaging to assess response to chemotherapy? (2008) (0)
Acknowledgement to the Reviewers (2007) (0)
Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (2018) (0)
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer. (2023) (0)
P-307Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal carcinoma: The phase 3 IMPALA study (2015) (0)
[Academic carriers in oncology and radiotherapy: Update for the readers of Bulletin du Cancer]. (2021) (0)
Iconography : Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma (2008) (0)
Hepatic arterial chemotherapy of 5 fluorouracil (5FU) combined with intravenous 5FU and folinic acid in patients with liver metastases of colorectal cancer (2001) (0)
Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply. (2018) (0)
Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions. (2023) (0)
Selenium and the Course of Mild Graves' Orbitopathy (2011) (0)
Prospective assessment of functional results and quality of life in patients treated for locally advanced anal canal carcinoma by high dose radio-chemotherapy (2001) (0)
Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial (2007) (0)
Organoids in digestive oncology: Inventory and perspectives (2020) (0)
6112 POSTER Health-related Quality of Life at 12 Months in Patients With Metastatic Colorectal Cancer (mCRC) Initiating a Treatment With Bevacizumab (Bv) Plus Chemotherapy (CT) – Results From the CONCERT French Non Interventional Study (2011) (0)
238 ORAL Are extra-hepatic metastases still a contra-indication for hepatic colorectal metastases resection? (2006) (0)
Iatrigger Project: Development and Validation of a Tool to Evaluate Adverse Drugs Events in Oncology Patients (2012) (0)
O.9 Capecitabine (XELODA®, X) and oxaliplatine (ELOXATIN®, LOHP) regimen (XELOX) in elderly patients with metastatic colorectal cancer (MCRC): a FNCLCC French Collaborative Group GERICO 02 phase II study (2007) (0)
[Palliative chemotherapy in colorectal cancer: new molecular drugs]. (1995) (0)
2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016) (2016) (0)
[The oncology residency program in French overseas]. (2022) (0)
[Secondary appearance of hypoglycemia caused by hyperinsulinism in a patient with malignant endocrine tumor of the pancreas]. (2000) (0)
Is intra-arterial hepatic chemotherapy painful? (2020) (0)
Bile Duct and Gallbladder Cancer: Chemotherapy and Radiotherapy (2007) (0)
Phase 2 of intra-arterial hepatic (IAH) bevacizumab with systemic chemotherapy (CT) in second line treatment of liver metastases of colorectal cancer (LMCRC). (2016) (0)
Iconography : Peritoneal carcinomatosis of colorectal origin (2008) (0)
[Intra-arterial hepatic chemotherapy. Experience of 200 cases]. (1994) (0)
[Salmonella enteritidis infection with dilatation of the bile ducts]. (1993) (0)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients. Authors' reply (2004) (0)
How to reduce the risk of recurrence after surgical treatment of colorectal liver metastases? (2011) (0)
Iconographies supplémentaires de l'article : A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment (2008) (0)
Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. (2018) (0)
6577 POSTER Investigating Potential Biomarkers for Survival With Erlotinib in Patients With Advanced Pancreatic Cancer – Results of the Phase II B021129 Study (2011) (0)
A phase I trial of intraperitoneal (IP) chemohyperthermia (CH) with oxaliplatin (L-OHP) and irinotecan (CPT-11) in patients (pts) with peritoneal carcinomatosis (PC): Pharmacokinetic (PK),tissue distribution and tolerance. (2004) (0)
Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy. (2014) (0)
2316 Efficacy and toxicity of second-line chemotherapy in patients with advanced oesophageal squamous cell carcinoma progressing after a first line of 5-fluorouracil and platinum-based therapy: An AGEO retrospective multicentric study (2015) (0)
Quantitative density evaluation of liver metastases on CT scan: A new tool to evaluate early the benefit of bevacizumab plus chemothrapy regimen. (2011) (0)
[Colorectal cancer: a better known and better treated disease?]. (1997) (0)
[Esophagectomy for epidermoid cancer discovered during evaluation of ENT cancer]. (1998) (0)
PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis (2012) (0)
Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitory of the response. (2014) (0)
508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) (2021) (0)
Phase II study of fotemustine-5 fulederfoline (FU-FOL) in metastatic colorectal carcinomas (CRC): Preliminary results (1993) (0)
Optimizing administration of third-line treatment in metastatic colorectal cancer. (2021) (0)
SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma (2022) (0)
Review of the Current Status of Kras Mutation Testing in France in 2011: The Flash-Kras Study (2012) (0)
Which Intraarterial Hepatic Chemotherapy for Liver Metastasis from Colorectal Carcinoma?1 (1988) (0)
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment. (2022) (0)
Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas (2018) (0)
Volumetric Modifications of Metastatic Liver Volumes after Dramatic Responses under Chemotherapy (2012) (0)
Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients’ management (2010) (0)
Role of tritherapy with fluorouracil/leucovorin, irinotécan and oxaliplatin in the treatment of metastatic colorectal cancer (2017) (0)
Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable? (2015) (0)
Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial (2012) (0)
Does systemic chemotherapy prior to surgery increase the operative risk of a major hepatectomy (2001) (0)
Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence. (2018) (0)
P-76 Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC (2021) (0)
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study. (2023) (0)
[Chemotherapy of digestive neuroendocrine tumors]. (1995) (0)
2131 Efficacy and safety of nab-paclitaxel (nab-P) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): The phase II COLO-001 trial (2015) (0)
104Treatment of oesophagus cancer by high dose rate brachytherapy(HDRB) (1998) (0)
Is liquid biopsy useful in patients with GI malignancies and exclusive peritoneal disease? (2023) (0)
1563P Early clinical trials in patients with pancreatic cancer: Assessment of factors limiting eligibility and effectiveness (2020) (0)
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study (2023) (0)
Review 3 rd St . Gallen EORTC Gastrointestinal Cancer Conference : Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer (2017) (0)
3018 POSTER Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/Oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial (2007) (0)
Predictive value of thymidylate synthase (ts) gene polymorphism for response to 5-FU in advanced colorectal cancer (CRC): Role of chromosome 18p allelic loss. (2004) (0)
Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity? (2019) (0)
Treatment of liver metastases and moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate postoperative chemotherapy: Feasibility and preliminary results (1997) (0)
1398PCANCER PATIENTS'WILLINGNESS TO USE IT FOR THEIR HEALTH. (2014) (0)
[Chemotherapy and surgery: how can resection of colorectal cancer metastases to the liver be optimized?]. (2008) (0)
Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer. (2015) (0)
Peritoneal carcinomatosis treatmnt with curative: Institut Gustave-Roussy experience (1997) (0)
SO-1 Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma (2022) (0)
Treatment of Advanced Gastric Cancer: Where We Are in 2003 (2003) (0)
DNA content analysis by flow cytometry in hepatocellular carcinoma (HCC) (1991) (0)
Phase II , randomized , biomarker identi fi cation trial ( MARK ) for erlotinib in patients with advanced pancreatic carcinoma (2014) (0)
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer. (2021) (0)
A Phase II Trial of Bevacizumab with Capecitabine in Progressive, Metastatic Well-Differentiated Digestive Endocrine Tumors (Better Study) (2012) (0)
[Clinical cases: a well-differentiated endocrine tumor]. (2006) (0)
434P Cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma: A single center experience (2022) (0)
Implementing Integrated Quality Assurance (SURCARE) for EORTC-JCOG 1527 / ESSO 02: Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Assessment of Liver Metastasis to Improve Surgical Planning (DREAM) (2019) (0)
P-0025 Modified Folfiri (mFolfiri) as Second Line Chemotherapy in Advanced Gastric Cancer (AGC) (2012) (0)
Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model (2021) (0)
[Colon and rectal tumours]. (2005) (0)
KRAS WT pancreatic adenocarcinomas: Another disease? (2023) (0)
Baseline carcinoembryonic antigen predicts response to IMM-101 in advanced pancreatic cancer: Data analysis from a randomised, open label, phase II study. (2017) (0)
Table of Contents for (9781402088995) Methods of Cancer Diagnosis, Therapy and Prognosis: Gastrointestinal Cancer by Hayat, M. A (2011) (0)
Proposal of a two-step dynamic prognostic stratification for stage IV sporadic pancreatic neuroendocrine tumors (2016) (0)
Outcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery. (2010) (0)
[Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer]. (2001) (0)
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology (2023) (0)
[Chemotherapy in locally advanced or metastatic colonic cancer]. (1998) (0)
[Efficiency and reproducibility of an intraperitoneal chemo-hyperthermia technique after complete resection of peritoneal carcinoma]. (1999) (0)
ASCO-Abstracts (2003) (0)
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973) (2018) (0)
Gastric linitis: Results of a French national survey confirming the specificity of this gastric neoplasm and the limited therapeutic options. (2010) (0)
Chemotherapy of pancreatic cancer. (2017) (0)
Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II tria (2011) (0)
Iconography : A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment (2008) (0)
Abstract No. 362: Percutaneoulty Implanted Ports for Intra-Arterial Chemotherapy: Predictive Factors of Catheter Functionality (2008) (0)
Impact of 177Lu-octreotate therapy on the spleen (2008) (0)
2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) (2015) (0)
Cancers de l'œsophage, de l'estomac, du pancréas et cancer colorectal (2006) (0)
Global ph 3, randomized, double-blind, placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20) + nab-paclitaxel & gemcitabine in pts with previously untreated, hyaluronan-high, stage iv pancreatic ductal adenocarcinoma. (2017) (0)
[Management of disclosed hepatic metastases]. (1996) (0)
Predictive value of thymidylate synthase (ts) gene polymorphism for response to 5-FU in advanced colorectal cancer (CRC): Role of chromosome 18p allelic loss (2004) (0)
Development of an aid to decision-making form (ADF) integrated into a major institutional program in oncology: A tool to support care goal identification. (2021) (0)
Current use and attitudes toward the use of information technologies in health care among cancer patients. (2014) (0)
1O A study of cancer dissemination from metastatic intermediates of hypermethylated colorectal patients reveals a new mode of collective migration (2020) (0)
563 Efficacy of the combination of etoposide (E) and cisplatinum (P) in the treatment of neuroendocrin digestive carcinoma (NEC) (1995) (0)
Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study. (2018) (0)
47 Gemcitabine versus GEMOX (gemcitabine + oxallplatin) in non resectable pancreatic adenocarcinoma: a GERCOR/GISCAD intergroup phase III (2003) (0)
Detection precoce des recidives locales par TEP-FDG apres un traitement par radiofrequence pulmonaire (2007) (0)
A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment. (2008) (0)
[Colorectal cancer in France: towards an improvement in therapy?]. (2004) (0)
No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer (2019) (0)
High-l-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer : Final results of a phase l i study , (2005) (0)
HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (2018) (0)
Radiolabelled therapy in the field of neuroendocrine tumors (2009) (0)
Subject Index Vol. 63, 2002 (2002) (0)
Hepatic arterial infusion (HAI) of oxaliplatin with either LV5FU2 or FOLFIRI in patients (pts) with refractory metastatic colorectal cancer (mCRC). (2011) (0)
[Management of colorectal cancer and its metastases to the liver]. (2008) (0)
[A desmoid tumor sensitive to hormonotherapy]. (1994) (0)
726PPrecision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial (2017) (0)
160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC) (2022) (0)
Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. (2021) (0)
Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II (2016) (0)
Abstract CT066: Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (2017) (0)
Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model (2021) (0)
Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008 (2009) (0)
[Closure of a large esophagotracheal fistula in esophageal cancer, using two endoprostheses: one tracheobronchial silicone-covered prosthesis and another: expandable silicone-covered metal esophageal prosthesis]. (1996) (0)
Retroperitoneal dissemination of colorectal ovarian metastases: Basis for rationale use of lymphadenectomy. (2011) (0)
586P Bidirectional chemotherapy for initially unresectable malignant peritoneal mesothelioma: Proof of concept of a new conversion strategy? (2020) (0)
Continuous infusion of 5-fluorouracil (5-FU) in neuroendocrine tumours (NET) (1999) (0)
[Prevention of colorectal cancer: what is the role of aspirin?]. (1992) (0)
[Rectal cancer Information dedicated to cancer patients and relatives]. (2006) (0)
P Comparison of four staging systems to predict overall survival rate in Indonesian hepatocellular carcinoma patients (2017) (0)
Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO). (2016) (0)
Role of the DNA mismatch repair system in the responsiveness of metastatic colorectal cancers to chemotherapy with CPT-11 (irinotecan) (2001) (0)
Contents Vol. 63, 2002 (2002) (0)
[Adjuvant treatment of resected colon cancers using a 5-fluorouracil-levamisole combination]. (1991) (0)
Multimodal treatment in colon cancer: recent advances and future prospects (1999) (0)
A phase I trial of intraperitoneal (IP) chemohyperthermia (CH) with oxaliplatin (L-OHP) and irinotecan (CPT-11) in patients (pts) with peritoneal carcinomatosis (PC): Pharmacokinetic (PK),tissue distribution and tolerance (2004) (0)
Multidisciplinary management of rectal cancer with synchronous metastasis (1998) (0)
SO-5 Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials (2022) (0)
First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228). (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michel P. Ducreux?

Michel P. Ducreux is affiliated with the following schools:

Michel P. Ducreux's Academic­Influence.com Rankings

Michel P. Ducreux's Degrees

Why Is Michel P. Ducreux Influential?

Michel P. Ducreux's Published Works

Published Works

What Schools Are Affiliated With Michel P. Ducreux?

Michel P. Ducreux's AcademicInfluence.com Rankings